Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.65
At close: Nov 12 EDT
$1.61
-0.04-2.42%
Pre-Market: 4:07 AM EDT
Comments
Loading...
InflaRx Analyst Ratings and Price Targets | NASDAQ:IFRX | Benzinga
InflaRx NV has a consensus price target of $11.33 based on the ratings of 7 analysts. The high is $22 issued by Guggenheim on November 10, 2025. The low is $3 issued by Oppenheimer on May 29, 2025. The 3 most-recent analyst ratings were released by Guggenheim, HC Wainwright & Co., and Oppenheimer on November 10, 2025, September 2, 2025, and May 29, 2025, respectively. With an average price target of $10.33 between Guggenheim, HC Wainwright & Co., and Oppenheimer, there's an implied 541.82% upside for InflaRx NV from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
HC Wainwright & Co.
Oppenheimer
Cantor Fitzgerald
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for InflaRx
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/10/2025 | 1266.46% | Guggenheim | $10 → $22 | Maintains | Buy | |||
09/02/2025 | 272.67% | HC Wainwright & Co. | → $6 | Assumes | → Buy | |||
05/29/2025 | 86.34% | Oppenheimer | $6 → $3 | Maintains | Outperform | |||
05/08/2025 | 272.67% | Oppenheimer | → $6 | Initiates | → Outperform | |||
04/29/2025 | 521.12% | Cantor Fitzgerald | → $10 | Initiates | → Overweight | |||
03/26/2025 | 521.12% | Guggenheim | $7 → $10 | Maintains | Buy | |||
03/21/2025 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
03/07/2025 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
01/16/2025 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
12/20/2024 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
11/15/2024 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
11/11/2024 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
09/25/2024 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
06/24/2024 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
06/06/2024 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
05/09/2024 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
03/22/2024 | 396.89% | HC Wainwright & Co. | $8 → $8 | Reiterates | Buy → Buy | |||
01/25/2024 | 396.89% | HC Wainwright & Co. | $9 → $8 | Maintains | Buy | |||
11/02/2023 | 1080.12% | Raymond James | $21 → $19 | Maintains | Strong Buy | |||
09/12/2023 | 459.01% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy | |||
08/31/2023 | 459.01% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy | |||
08/11/2023 | 459.01% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy | |||
05/12/2023 | 459.01% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy | |||
05/12/2023 | 1204.35% | Raymond James | $25 → $21 | Maintains | Strong Buy | |||
04/21/2023 | 459.01% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy | |||
04/06/2023 | — | Guggenheim | — | Upgrade | Neutral → Buy | |||
04/06/2023 | 1452.8% | Raymond James | $8 → $25 | Maintains | Strong Buy | |||
04/05/2023 | 396.89% | Guggenheim | → $8 | Upgrade | Neutral → Buy | |||
04/05/2023 | 521.12% | HC Wainwright & Co. | $6 → $10 | Reiterates | → Buy | |||
04/05/2023 | — | LifeSci Capital | — | Upgrade | Market Perform → Outperform | |||
03/23/2023 | 272.67% | HC Wainwright & Co. | → $6 | Reiterates | → Buy | |||
01/06/2023 | 272.67% | HC Wainwright & Co. | $8 → $6 | Maintains | Buy |
FAQ
What is the target price for InflaRx (IFRX) stock?
The latest price target for InflaRx (NASDAQ:IFRX) was reported by Guggenheim on November 10, 2025. The analyst firm set a price target for $22.00 expecting IFRX to rise to within 12 months (a possible 1266.46% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for InflaRx (IFRX)?
The latest analyst rating for InflaRx (NASDAQ:IFRX) was provided by Guggenheim, and InflaRx maintained their buy rating.
When was the last upgrade for InflaRx (IFRX)?
The last upgrade for InflaRx NV happened on April 6, 2023 when Guggenheim raised their price target to N/A. Guggenheim previously had a neutral for InflaRx NV.
When was the last downgrade for InflaRx (IFRX)?
There is no last downgrade for InflaRx.
When is the next analyst rating going to be posted or updated for InflaRx (IFRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of InflaRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for InflaRx was filed on November 10, 2025 so you should expect the next rating to be made available sometime around November 10, 2026.
Is the Analyst Rating InflaRx (IFRX) correct?
While ratings are subjective and will change, the latest InflaRx (IFRX) rating was a maintained with a price target of $10.00 to $22.00. The current price InflaRx (IFRX) is trading at is $1.61, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
